©2024 Stanford Medicine
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Not Recruiting
Trial ID: NCT00490061
Purpose
We propose to combine lapatinib with RT alone in patients with locally advanced head and neck
cancer who cannot tolerate chemotherapy. The main objective of the study is to determine the
efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression
(TTP) in this group of patients. In addition, we will determine the 2-year locoregional
control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these
patients. We will also evaluate the profile and frequency of late toxicity, specifically
mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with
locally advanced head and neck squamous cell carcinoma (HNSCC).
Official Title
A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.
Stanford Investigator(s)
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Nancy Fischbein
Professor of Radiology and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) , of Neurology, of Neurosurgery & of Radiation Oncology
Harlan Pinto
Associate Professor of Medicine (Oncology) and of Otolaryngology - Head & Neck Surgery
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Eligibility
Inclusion Criteria:
- Newly diagnosed stage III-IV HNSCC, pathologically confirmed (HNSCC from unknown
primary sites are allowed)
- No evidence of distant metastasis
- No prior radiation therapy to the head and neck sites.
- Able to sign a study-specific informed consent form.
- Women of childbearing potential and men with partners capable of producing offspring
must be willing to practice acceptable methods of birth control to prevent pregnancy.
- Left ventricular ejection fraction (LVEF) within the institutional normal range as
measured by ECHO (If ECHO cannot be performed or if the Investigator feels that it is
not conclusive to evaluate LVEF, then a MUGA scan should be performed).
- Having one of the following parameters that would preclude the use of concurrent CRT:
- ECOG PS > 2.
- Creatinine > 1.3 or calculate or measure creatinine clearance < 60 ml/min.
- AST or ALT > 1.5 times normal limit but < 3 times normal limit
- Total bilirubin > 1.5 mg/dL but < 3mg/dL
- History of hearing loss that would preclude cisplatin chemotherapy. These would
include the existing need of a hearing aid or a >= 25 decibel shift over 2
contiguous frequencies on a pretreatment hearing test.
- Pre-existing peripheral neuropathy that would preclude cisplatin chemotherapy
- Refuse or cannot tolerate chemotherapy
- Age 18 years or older
Exclusion Criteria:
- Known hypersensitivity to lapatinib or any of the excipients of this product
(quinazolines).
- Uncontrolled angina, arrhythmia or congestive heart failure at the time of HNSCC
diagnosis and treatment.
- History of myocardial infarction < 6 months from study entry.
- Treatment with a non-approved or investigational drug within 30 days before Day 1 of
study treatment.
- Prior treatment with EGFR or Her2/Neu directed therapies.
- HIV-positive patients receiving combination anti-retroviral therapy are excluded from
the study because of possible pharmacokinetic interactions with Lapatinib.
- Absolute neutrophil count < 1500/uL
Intervention(s):
drug: Lapatinib
device: G.E. Healthcare 1.5T MR, systems revision 12.0 M5
procedure: Radiotherapy (radiation)
device: DCE-MRI
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Brian Khong
6507254777